On the horizon: promising investigational antiretroviral agents

Area of Science:

• Virology
• Infectious Diseases
• Pharmacology

Background:

• Human Immunodeficiency Virus (HIV) infection impacts millions globally, with significant mortality.
• Increasing resistance to existing antiretrovirals necessitates the development of new therapeutic agents.
• The standard of care involves multiple antiretrovirals, leading to a rise in resistant HIV strains.

Purpose of the Study:

• To review promising Human Immunodeficiency Virus (HIV) agents in Phase II-III clinical development.
• To assess the clinical efficacy, pharmacology, resistance profiles, and tolerability of novel antiretrovirals.
• To highlight emerging drug classes and their potential to treat resistant HIV strains.

Main Methods:

• Review of clinical trial data for antiretroviral agents in development.
• Assessment of pharmacological properties, resistance patterns, and patient tolerability.
• Categorization of agents by drug class, including nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, attachment inhibitors, CCR5 coreceptor antagonists, and maturation inhibitors.

Main Results:

• Several agents from existing antiretroviral classes (nucleosides, non-nucleosides, protease inhibitors) show promise.
• Novel pharmacologic classes, including attachment inhibitors, CCR5 coreceptor antagonists, and maturation inhibitors, are entering clinical trials.
• Early studies indicate potential for improved activity against resistant HIV strains.

Conclusions:

• Emerging antiretrovirals from both established and novel classes offer hope for treating drug-resistant Human Immunodeficiency Virus (HIV).
• These agents aim to reduce viral load, increase CD4+ cell counts, and prolong survival with minimal adverse effects.
• Continued development of novel antiretrovirals is crucial for managing the evolving challenges of HIV treatment.